共 50 条
- [1] A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trialJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Hu, BoyuNastoupil, Loretta J.Holmes, HoustonHamdan, AyadKanate, AbrahamFarooq, UmarCherry, MohamadBrem, ElizabethPinter-Brown, Lauren C.Ermann, Daniel ArthurHusnain, MuhammadMicklethwaite, KennethRizvi, SyedHammad, AshleyThompson, BenZudaire, EnriquePortella, SocorroHamadani, MehdiEssell, JamesO'Brien, Susan Mary
- [2] A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Berdeja, Jesus G.Martin, Thomas G.Rossi, AdrianaEssell, James H.Siegel, David Samuel DiCapuaMailankody, ShamSaini, NeerajHolmes, HoustonDhakal, BinodGasparetto, Cristina J.Parekh, Samir S.Portella, SocorroLedergor, GuyHammad, AshleyDavi, FrancoSkoble, JustinGarner, ElizabethKanner, Steven BrianRizvi, SyedJagannath, Sundar
- [3] Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from IndiaBLOOD, 2022, 140 : 4610 - 4611Karulkar, AtharvaJain, HasmukhShah, ShreshthaKhan, AaliaJaiswal, AnkeshFirfiray, AfrinSuvasia, PrashantSuvasia, PriyanshiPendhari, JuberAsija, SweetyChowdury, AmbalikaBanik, AnkitRavikumar, SmrithiSharma, NehaPoojary, MinalHiregoudar, SumathiDesai, PreetiNavkudkar, AnishaRajadhyaksha, SunilThorat, JayashreeTembhare, Prashant R.Nisar, AlbeenaSengar, ManjuStroncek, David F.Highfill, StevenShah, Nirali N.Narula, GauravPurwar, Rahul
- [4] Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHLBLOOD, 2020, 136Zhou, LiliHuang, JiaqiZhu, ShiguiYao, XinYe, ShiguangZhu, JudyZheng, ChengxiaoChen, ShiyiLi, YanfengLan, LipingChen, ShichengGuo, LinZhang, QingsongZheng, JiangqinWang, RirfeiHong, YiRen, JiaqiangZhang, LiZhang, WenjunTang, XiaochenWang, JunbangLiu, JieHumphries, MichaelLi, PingYao, YihongLiang, Aibin
- [5] First-in-human study with UCART19, an allogeneic anti-CD19 CAR T-cell product, in high risk adult patients with CD19+ R/R B-cell ALL: Preliminary results of CALM studyBONE MARROW TRANSPLANTATION, 2018, 53 : 21 - 22Graham, CharlotteYallop, DeborahJozwik, AgnieszkaPatten, PiersDunlop, AlanEllard, RoseStewart, OrlaPotter, VictoriaMetaxa, VictoriaKassam, ShireenFarzaneh, FarzinDevereux, StephenPagliuca, AntonioZinai, AminaBinlich, FlorenceDupouy, SandraPhilippe, AnneBalandraud, SvetlanaPoirot, CamilleSimon, FlavieKonto, CyrilBermingham, CandyMufti, GhulamBenjamin, Reuben
- [6] First-in-Human Study of ET019003, a Next Generation Anti-CD19 T-Cell Therapy, in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)BLOOD, 2019, 134He, PengchengLiu, HongLiu, HaiboLuo, MinaFeng, HuiLi, QijingChang, QiShi, BingyiLiu, Cheng
- [7] Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysisCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 179Chen, SifeiZhang, YuchenFang, ChenglongZhang, NianqinWang, YuChen, RunkaiLi, YuhuaTu, Sanfang
- [8] Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Liang, AibinYe, ShiguangLi, PingHuang, JiaqiZhu, ShiguiYao, XinZhou, LiliXu, YangyangZhu, JudyZheng, ChengxiaoChen, ShiyiLan, LipingLv, XiaotengWei, YutianHumphries, MichaelYao, Yihong
- [9] A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)BLOOD, 2022, 140 : 9457 - 9458O'Brien, SusanNastoupil, Loretta J.Essell, JamesDsouza, LyHart, DougMatsuda, EmiriSatterfield, TarahNesheiwat, ToniaHammad, AshleyDavi, FrancoChung, ShallyShamsi, S. AsimBryan, MaraSkoble, JustinGarner, ElizabethKanner, StevenRizvi, SyedHolmes, Houston
- [10] Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical studyBlood Cancer Journal, 12Junfang YangJiaping HeXian ZhangJingjing LiZhenguang WangYongliang ZhangLiyuan QiuQionglu WuZhe SunXun YeWenjie YinWei CaoLianjun ShenMartina SerschPeihua Lu